IMMUNIC, INC.
IMUXNext catalyst
IMU-838 tablets
Multiple Sclerosis, Relapsing-Remitting
Get an email about IMUX's next catalysts
Track IMMUNIC (IMUX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
3 upcoming, 1 past
IMUX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.82 | FQ end Sep/2026 | Call: tbd
IMU-838 tablets Phase 3 Est. Readout (ENSURE-1)
Estimated primary completion for IMU-838 tablets trial (NCT05201638) in Multiple Sclerosis, Relapsing-Remitting. Topline data typically follows completion by weeks to months.
SourcePhase 3
Immunic is advancing its MS drug toward Phase 3 data readout, with results expected by year-end 2026. The company has progressed the development program and anticipates releasing key efficacy and safety data in the coming months.
SourceHow IMUX's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMU-838 tablets | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
IMU-838 | Phase 3 | Multiple Sclerosis | - | - |
Frequently asked questions
What is in IMMUNIC, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in IMMUNIC, INC.'s (IMUX) pipeline across Phase 3. Its lead program is IMU-838 tablets (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IMMUNIC, INC.'s next FDA catalyst?→
IMMUNIC, INC.'s (IMUX) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMUX biotech catalysts?→
Add IMUX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IMMUNIC, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.